Last updated: 5 September 2024 at 5:27pm EST

Andrew L. Guggenhime M.B.A. Net Worth




The estimated Net Worth of Andrew Guggenhime is at least $12.4 Million dollars as of 19 August 2024. Mr Guggenhime owns over 8,000 units of Vaxcyte stock worth over $11,890,956 and over the last 19 years he sold PCVX stock worth over $0. In addition, he makes $540,711 as Pres & CFO at Vaxcyte.

Mr A PCVX stock SEC Form 4 insiders trading

Mr has made over 42 trades of the Vaxcyte stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 8,000 units of PCVX stock worth $42,800 on 19 August 2024.

The largest trade he's ever made was exercising 36,000 units of Vaxcyte stock on 25 August 2022 worth over $192,600. On average, Mr trades about 5,718 units every 46 days since 2006. As of 19 August 2024 he still owns at least 104,720 units of Vaxcyte stock.

You can see the complete history of Mr Guggenhime stock trades at the bottom of the page.





Mr. Andrew L. Guggenhime M.B.A. biography

Andrew L. Guggenhime M.B.A. is the Pres & CFO at Vaxcyte.

What is the salary of Mr A?

As the Pres & CFO of Vaxcyte, the total compensation of Mr A at Vaxcyte is $540,711. There are 3 executives at Vaxcyte getting paid more, with Grant E. Pickering M.B.A. having the highest compensation of $938,361.



How old is Mr A?

Mr A is 53, he's been the Pres & CFO of Vaxcyte since . There are 2 older and 6 younger executives at Vaxcyte. The oldest executive at Vaxcyte, Inc. is Paul W. Sauer M.B.A., MBA, 60, who is the Sr. VP of Process Devel. & Manufacturing.

What's Mr A's mailing address?

Andrew's mailing address filed with the SEC is C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA, 94070.

Insiders trading at Vaxcyte

Over the last 12 years, insiders at Vaxcyte have traded over $60,439,674 worth of Vaxcyte stock and bought 1,293,000 units worth $20,688,000 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Capital Management, L.P.Ra ..., and Llp Abingworth. On average, Vaxcyte executives and independent directors trade stock every 23 days with the average trade being worth of $2,563,959. The most recent stock trade was executed by Jim Wassil on 3 September 2024, trading 10,000 units of PCVX stock currently worth $24,200.



What does Vaxcyte do?

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.



What does Vaxcyte's logo look like?

Vaxcyte, Inc. logo

Complete history of Mr Guggenhime stock trades at PDL Biopharma Inc, Vaxcyte, and Metacrine

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
19 Aug 2024 Andrew Guggenhime
PRESIDENT AND CFO
Option 8,000 $5.35 $42,800
19 Aug 2024
104,720
18 Jul 2024 Andrew Guggenhime
PRESIDENT AND CFO
Option 8,000 $5.35 $42,800
18 Jul 2024
104,720
18 Jun 2024 Andrew Guggenhime
PRESIDENT AND CFO
Option 8,000 $5.35 $42,800
18 Jun 2024
104,720
20 May 2024 Andrew Guggenhime
PRESIDENT AND CFO
Option 8,000 $5.35 $42,800
20 May 2024
103,679
18 Apr 2024 Andrew Guggenhime
PRESIDENT AND CFO
Option 8,000 $5.35 $42,800
18 Apr 2024
103,679
18 Mar 2024 Andrew Guggenhime
PRESIDENT AND CFO
Option 8,000 $5.35 $42,800
18 Mar 2024
103,679
20 Feb 2024 Andrew Guggenhime
PRESIDENT AND CFO
Option 8,000 $5.35 $42,800
20 Feb 2024
87,474
18 Jan 2024 Andrew Guggenhime
PRESIDENT AND CFO
Option 8,000 $5.35 $42,800
18 Jan 2024
87,474
18 Dec 2023 Andrew Guggenhime
PRESIDENT AND CFO
Option 8,000 $5.35 $42,800
18 Dec 2023
87,474
14 Dec 2023 Andrew Guggenhime
PRESIDENT AND CFO
Option 14,000 $5.35 $74,900
14 Dec 2023
93,474
20 Nov 2023 Andrew Guggenhime
PRESIDENT AND CFO
Option 8,000 $5.35 $42,800
20 Nov 2023
87,474
18 Oct 2023 Andrew Guggenhime
PRESIDENT AND CFO
Option 8,000 $5.35 $42,800
18 Oct 2023
87,474
30 Dec 2022 Andrew Guggenhime
PRESIDENT AND CFO
Option 23,691 $5.35 $126,747
30 Dec 2022
61,229
19 Sep 2022 Andrew Guggenhime
PRESIDENT AND CFO
Option 3,100 $5.35 $16,585
19 Sep 2022
40,638
25 Aug 2022 Andrew Guggenhime
PRESIDENT AND CFO
Option 36,000 $5.35 $192,600
25 Aug 2022
59,840
18 Aug 2022 Andrew Guggenhime
PRESIDENT AND CFO
Option 3,100 $5.35 $16,585
18 Aug 2022
45,287
18 Jul 2022 Andrew Guggenhime
PRESIDENT AND CFO
Option 3,100 $5.35 $16,585
18 Jul 2022
45,287
8 Jul 2022 Andrew Guggenhime
PRESIDENT AND CFO
Option 3,100 $5.35 $16,585
8 Jul 2022
45,287
18 May 2022 Andrew Guggenhime
PRESIDENT AND CFO
Option 3,100 $5.35 $16,585
18 May 2022
45,287
18 Apr 2022 Andrew Guggenhime
PRESIDENT AND CFO
Option 3,100 $5.35 $16,585
18 Apr 2022
43,725
18 Mar 2022 Andrew Guggenhime
PRESIDENT AND CFO
Option 3,100 $5.35 $16,585
18 Mar 2022
43,725
1 Mar 2022 Andrew Guggenhime
PRESIDENT AND CFO
Option 6,200 $5.35 $33,170
1 Mar 2022
9,325
23 Dec 2021 Andrew Guggenhime
PRESIDENT AND CFO
Option 3,100 $5.35 $16,585
23 Dec 2021
6,225
18 Nov 2021 Andrew Guggenhime
PRESIDENT AND CFO
Option 3,100 $5.35 $16,585
18 Nov 2021
6,225


Vaxcyte executives and stock owners

Vaxcyte executives and other stock owners filed with the SEC include: